v3.23.1
Significant Agreements (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Product Liability Contingency [Line Items]    
Agreement description The Company and Cipla will each be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”), in addition to which, Cipla will reimburse the Company an amount equal to 10% of aggregate Direct Costs upon the achievement of the development milestones set forth in the table below, potentially bringing the sharing of Direct Costs to a 50/50 basis. The Company will continue to share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis  
Transaction cost $ 22,000  
Revenue related to the research and development service 6,071 $ 5,169
Deferred revenue, current 1,339 939
Cipla Agreement [Member] | Cipla Technologies LLC [Member]    
Product Liability Contingency [Line Items]    
Proceeds from related party debt 22,000  
Transaction price 7,400  
Deferred revenue 800  
Deferred revenue 6,200  
Deferred revenue, current 1,300  
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Research and Development Service [Member]    
Product Liability Contingency [Line Items]    
Transaction cost 12,000  
Revenue related to the research and development service 6,100 1,400
Cipla Agreement [Member] | Cipla Technologies LLC [Member] | Irrevocable License [Member]    
Product Liability Contingency [Line Items]    
Transaction cost $ 10,000  
Collaboration And License Agreement [Member] | Research and development [Member]    
Product Liability Contingency [Line Items]    
Revenue related to the research and development service   $ 3,700